Perspective Therapeutics (CATX) Company Overview

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics' radiopharmaceuticals offer potential oncology applications by combining diagnostics with targeted therapeutics. I like the company's theranostics approach that delivers radiation directly to tumors. This can potentially minimize healthy tissue damage, and it has already had promising early results in neuroendocrine tumors. Currently, CATX's main candidates are VMT01 for melanoma and VMT-α-NET for neuroendocrine tumors. They're both in Phase 1/2 trials, and VMT01 has Fast Track Designation.

Perspective Therapeutics' novel alpha emitter PRRT shows promise in early trials, with manageable toxicity and durable disease control in GEP-NETs and melanoma. Strong cash position allows CATX to continue research for years, despite current market skepticism and a significant drop in valuation. Alpha emitter PRRT offers a potentially safer alternative to beta emitters, but faces challenges in manufacturing, handling, and market uptake.

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

SEATTLE, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced six updates on the Company's radiopharmaceutical programs being presented at the 37th Annual Congress of the European Association of Nuclear Medicine ("EANM") held in Hamburg, Germany, from October 19-23, 2024.

SEATTLE, Oct. 16, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today is celebrating the first shipment and patient dosing from its second manufacturing facility for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals.

SEATTLE, Oct. 11, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 are being presented at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.

SEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (“SMR”), being held on October 10-13, 2024 in New Orleans, Louisiana.

Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma.